Bone metastasis is characterized by the spreading of cancerous cells from their original site to a bone. All types of cancer can show bone-metastasis. However, it is estimated that breast cancer and prostate cancer are commonly associated with the disease. The medical condition is frequent for spine, pelvis, and thighs. Urinary incontinence, bowel incontinence, and hypercalcemia are some of the common symptoms of the disease. The increasing prevalence of bone metastasis is expected to be a major driver for the market growth during the forecast period. According to a study published in the Oncology Reviews Journal in 2017, the relative occurrence of bone metastasis was estimated to be around 65 to 75% for both breast and prostate cancers suffering patients, respectively. Moreover, the growing geriatric population, increasing healthcare expenditures, and increasing R&D in the market are estimated to drive the market growth during the forecast period. According to the American Society of Clinical Oncology in 2016, approximately 60% of the total cancer patients aged 65 years or more. However, factors such as lack of healthcare services in low-income countries, the high cost of treatment, and related side effects are estimated to restrain the market growth during the forecast period. According to a study published in the Journal of Spine Surgery in 2017, the mean total cost of therapeutic modalities such as vertebroplasty was estimated to be about USD 14,114 in 2014.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5776

The global bone metastasis market is expected to grow at an approximate CAGR of 8.4% during the forecast period

Intended Audience

• Pharmaceutical Companies
• Biotechnological Institutes
• Government and Private Laboratories
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Market Research and Consulting Service Providers

Segmentation

The global bone metastasis market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.

On the basis of diagnosis, the market is categorized into biopsy, blood test, imaging, and others. The imaging segment is sub-segmented into X-ray, bone scintigraphy, computerized tomography, magnetic resonance imaging, positron emission tomography, and others.

On the basis of the treatment, the market is segmented into medical therapies, surgery, medication, and others. The medical therapies segment is sub-segmented into chemotherapy, targeted therapy, hormone therapy, ablation therapy, and others. The ablation therapy segment is further segmented into radiofrequency ablation, cryoablation, and others. The surgery segment is sub-segmented into vertebroplasty, kyphoplasty, and others. The medication segment is sub-segmented into pain medications, bone building medications, and others. The pain medication segment is sub-segmented into ibuprofen, morphine, and others. The bone-building medications segment is sub-segmented into corticosteroids, bisphosphonates, and others. The bisphosphonates segment is further segmented into teriparatide, pamidronate, medronate, and others.

On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/bone-metastasis-market-5776